Becky Bates

Drotrecogin Alfa (activated) Improves In-hospital and 90-day Survival in Patients With Severe Sepsis and Community-acquired Pneumoni

Richard G. Wunderink, Sachin Yende, Pierre‐François Laterre et al. · CHEST Journal · 2003 · 247 citations

Veterinary Medicine, Pharmacology, Pharmacotherapy +10

Severe community-acquired pneumonia as a cause of severe sepsis: Data from the PROWESS study*

Pierre‐François Laterre, Gary Garber, Howard Levy et al. · Critical Care Medicine · 2005 · 197 citations

Medicine, Internal Medicine, Pharmacotherapy +17

Safety, Pharmacokinetics, and Pharmacodynamics of Drotrecogin Alfa (Activated) in Children With Severe Sepsis

Phil Barton, André C. Kalil, Simon Nadel et al. · PEDIATRICS · 2004 · 125 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Benefit/risk profile of drotrecogin alfa (activated) in surgical patients with severe sepsis

Philip S. Barie, Mark D. Williams, Jill Shwed McCollam et al. · The American Journal of Surgery · 2004 · 109 citations

Veterinary Medicine, Pharmacotherapy, Surgery +17

The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): Role, methodology, and results*

Jean-François Dhainaut, Pierre-François Laterre, Steven P. LaRosa et al. · Critical Care Medicine · 2003 · 92 citations

Medicine, Internal Medicine, Pharmacotherapy +16